Combining prelamin A accumulation and oxidative stress: A strategy to target glioblastoma

Area of Science:

• Neuro-oncology
• Cellular biology
• Drug discovery

Background:

• Glioblastoma is an aggressive brain tumor with limited treatment options.
• Current therapies offer modest survival benefits, necessitating novel therapeutic strategies.
• Glioblastoma stem cells drive tumor aggressiveness and recurrence.

Purpose of the Study:

• To investigate a novel therapeutic strategy targeting prelamin A processing in glioblastoma.
• To evaluate the efficacy of inhibiting farnesyltransferase using SCH66336 (Lonafarnib) in glioblastoma cells.
• To assess the combined effect of SCH66336 and Menadione on glioblastoma stem cells.

Main Methods:

• Inhibition of farnesyltransferase with SCH66336 to promote prelamin A accumulation.
• Induction of oxidative stress using Menadione in glioblastoma cells.
• Assessment of cell proliferation, stemness markers, and viability in patient-derived glioblastoma stem cells.

Main Results:

• SCH66336 treatment promoted prelamin A accumulation, increasing glioblastoma cell susceptibility to oxidative stress.
• Combined SCH66336-Menadione treatment reduced glioblastoma stem cell proliferation and viability.
• The combined treatment modified the expression of stemness markers in glioblastoma stem cells.
• Normal human astrocytes were spared from the toxic effects of the combined treatment.

Conclusions:

• Inhibiting prelamin A processing is a potential strategy to reduce glioblastoma aggressiveness.
• This approach enhances therapeutic outcomes, particularly for treatment-resistant glioblastoma stem cell populations.
• Disrupting prelamin A processing could serve as a complementary strategy in glioblastoma therapy.